Paying user area
Try for free
UnitedHealth Group Inc. pages available for free this week:
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Analysis of Reportable Segments
- Common Stock Valuation Ratios
- Dividend Discount Model (DDM)
- Net Profit Margin since 2005
- Operating Profit Margin since 2005
- Price to Earnings (P/E) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to UnitedHealth Group Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Adjustment to Net Income (Loss): Mark to Market Available-for-sale Securities
UnitedHealth Group Inc., adjustment to net earnings attributable to UnitedHealth Group common shareholders
US$ in millions
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
The financial data reveals distinct trends in both reported and adjusted net earnings attributable to the common shareholders over the five-year period ending December 31, 2024.
- Reported Net Earnings
- From 2020 to 2023, the reported net earnings show a consistent upward trajectory, increasing from $15,403 million to $22,381 million. This reflects a substantial growth over the four years, suggesting strong operational performance and profitability during this period.
- However, in 2024, there is a notable decline in reported net earnings, decreasing sharply to $14,405 million. This represents a significant reduction from the prior year's peak and indicates a potential challenge or one-time event affecting the company's profitability in that year.
- Adjusted Net Earnings
- The adjusted net earnings trend is similar initially but less volatile. From $16,150 million in 2020, the figure sees a modest increase reaching $16,372 million in 2021, and a further gradual increase to $16,919 million in 2022.
- In 2023, adjusted net earnings experience a considerable jump to $23,188 million, which may reflect adjusted improvements in operational efficiency or one-time adjustments not impacting reported earnings directly.
- In 2024, adjusted net earnings drop significantly to $14,150 million, closely mirroring the decrease in reported net earnings. This sharp decrease after a peak suggests the impact of exceptional circumstances affecting overall profitability when adjusted for any non-recurring items.
- Insights on Trends
- Overall, both reported and adjusted net earnings demonstrate steady growth through 2023, culminating in a strong profit year before a marked decline in 2024. This pattern highlights a possible economic, operational, or market-related disruption affecting earnings during the final year in the dataset.
- The similarity in trend direction for both reported and adjusted figures, particularly the significant dip in 2024, emphasizes that the underlying factors impacting profitability were material and affected both presented and normalized financial measures.
Adjusted Profitability Ratios: Mark to Market Available-for-sale Securities (Summary)
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
The analysis of the financial metrics over the given periods reveals several notable trends in profitability and efficiency ratios.
- Net Profit Margin
- The reported net profit margin remained relatively stable from 2020 to 2023, fluctuating between 6.03% and 6.25%, with a slight peak in 2022. However, there was a significant decline to 3.65% in 2024. The adjusted net profit margin followed a similar pattern, showing a gradual decrease from 6.32% in 2020 to 5.25% in 2022, a recovery to 6.31% in 2023, and then a marked drop to 3.58% in 2024. This indicates a notable erosion in profitability in the most recent period, after a phase of moderate variation.
- Return on Equity (ROE)
- Reported ROE exhibited an upward trend from 23.52% in 2020, reaching its peak at 25.87% in 2022, followed by a slight decline to 25.22% in 2023. Subsequently, there was a sharp decrease to 15.55% in 2024. Adjusted ROE also showed a similar trajectory, initially decreasing from 24.66% in 2020 to 21.75% in 2022, rebounding to 26.13% in 2023, and then falling significantly to 15.27% in 2024. Overall, the year 2024 presented a considerable contraction in equity returns, reversing prior gains.
- Return on Assets (ROA)
- The reported ROA stayed broadly consistent from 7.81% in 2020 through 8.19% in 2022 and 8.18% in 2023, before declining sharply to 4.83% in 2024. Adjusted ROA demonstrated more variability: starting at 8.19% in 2020, it decreased to 6.89% in 2022, increased to 8.47% in 2023, and then dropped significantly to 4.74% in 2024. This suggests a similar pattern of steady asset efficiency followed by a notable downturn in the latest period.
In summary, the data indicates that the company experienced relative stability or slight improvements in profitability and efficiency ratios from 2020 through 2023, with some fluctuations in adjusted figures. However, across all key performance indicators—net profit margin, ROE, and ROA—there was a pronounced decline in 2024, signaling deteriorating financial performance and reduced returns on both equity and assets in the most recent year.
UnitedHealth Group Inc., Profitability Ratios: Reported vs. Adjusted
Adjusted Net Profit Margin
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
2024 Calculations
1 Net profit margin = 100 × Net earnings attributable to UnitedHealth Group common shareholders ÷ Revenues, customers
= 100 × ÷ =
2 Adjusted net profit margin = 100 × Adjusted net earnings attributable to UnitedHealth Group common shareholders ÷ Revenues, customers
= 100 × ÷ =
- Reported Net Earnings
- Reported net earnings attributable to common shareholders increased steadily from 15,403 million US dollars in 2020 to a peak of 22,381 million US dollars in 2023, indicating consistent profitability growth over this period. However, in 2024, there was a significant decline to 14,405 million US dollars, reversing the previous upward trend.
- Adjusted Net Earnings
- Adjusted net earnings showed a more modest increase from 16,150 million US dollars in 2020 to 16,919 million in 2022. A substantial jump occurred in 2023, reaching 23,188 million US dollars, surpassing prior levels. Similar to reported earnings, adjusted net earnings fell sharply in 2024 to 14,150 million US dollars, indicating a notable reduction in profitability on an investment-adjusted basis.
- Reported Net Profit Margin
- The reported net profit margin displayed relative stability from 2020 through 2023, fluctuating slightly between 6.03% and 6.25%. This reflects consistent operational efficiency and profit generation relative to total revenue. In 2024, however, this margin declined markedly to 3.65%, pointing to reduced profitability or increased costs impacting net earnings relative to revenue.
- Adjusted Net Profit Margin
- Adjusted net profit margin declined gradually from 6.32% in 2020 to 5.25% in 2022, indicating a reduction in profitability efficiency on an adjusted basis. In 2023, the margin rebounded to 6.31%, aligning closely with earlier margin levels. Nonetheless, a sharp decrease to 3.58% in 2024 reflects a substantial weakening in profitability after adjustment for investment factors.
- Overall Trends and Insights
- Both reported and adjusted earnings exhibited growth through most of the observed period, culminating in peak values in 2023. Profit margins remained relatively stable with minor fluctuations until 2023, suggesting consistent profitability. The year 2024 represents a turning point, with significant declines in net earnings and profit margins, highlighting potential operational or market challenges that affected financial performance. The near-parallel trends in reported and adjusted figures suggest that the core business operations and investment adjustments both contributed to these financial outcomes.
Adjusted Return on Equity (ROE)
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
2024 Calculations
1 ROE = 100 × Net earnings attributable to UnitedHealth Group common shareholders ÷ Shareholders’ equity attributable to UnitedHealth Group
= 100 × ÷ =
2 Adjusted ROE = 100 × Adjusted net earnings attributable to UnitedHealth Group common shareholders ÷ Shareholders’ equity attributable to UnitedHealth Group
= 100 × ÷ =
The analyzed financial data reveal several key trends in the net earnings and return on equity (ROE) for the subject company over the five-year period presented.
- Reported Net Earnings
- Reported net earnings attributable to common shareholders show a consistent upward trajectory from 2020 through 2023, rising from $15,403 million to a peak of $22,381 million. However, in 2024, there is a notable decline to $14,405 million, representing a significant reduction after several years of growth.
- Adjusted Net Earnings
- Adjusted net earnings follow a somewhat different pattern. From 2020 to 2022, adjusted net earnings increase modestly from $16,150 million to $16,919 million, indicating moderate growth in earnings after adjustments. In 2023, there is a pronounced increase to $23,188 million, surpassing the reported figure for that year. Similar to reported earnings, 2024 sees a sharp decrease in adjusted earnings down to $14,150 million.
- Reported Return on Equity (ROE)
- The reported ROE percentages display steady improvement from 2020 through 2022, moving from 23.52% to a high of 25.87%. In 2023, there is a slight decrease to 25.22%, followed by a more pronounced drop to 15.55% in 2024, paralleling the earnings decline.
- Adjusted Return on Equity (ROE)
- Adjusted ROE shows a different trend pattern. Starting at 24.66% in 2020, it decreases steadily through 2022 to 21.75%. Then, in 2023, adjusted ROE rebounds sharply to 26.13%, marking the highest point in the period. By 2024, adjusted ROE falls substantially to 15.27%, consistent with the declines seen in net earnings.
Overall, the data suggest a period of growth in both earnings and profitability metrics until 2023, with noticeable strength in adjusted figures during that year. The following year, 2024, demonstrates a considerable downturn across all reported and adjusted financial indicators. The decline in 2024 could warrant further investigation to identify underlying causes such as changes in operational performance, market conditions, or one-off events affecting earnings and equity returns.
Adjusted Return on Assets (ROA)
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
2024 Calculations
1 ROA = 100 × Net earnings attributable to UnitedHealth Group common shareholders ÷ Total assets
= 100 × ÷ =
2 Adjusted ROA = 100 × Adjusted net earnings attributable to UnitedHealth Group common shareholders ÷ Total assets
= 100 × ÷ =
The financial data reveals several notable trends in the reported and adjusted earnings as well as return on assets (ROA) for the periods from 2020 to 2024. Both reported and adjusted net earnings attributable to common shareholders show a general increase from 2020 through 2023, followed by a marked decline in 2024.
- Net Earnings
-
Reported net earnings increased steadily from 15,403 million US dollars in 2020 to a peak of 22,381 million in 2023, representing consistent growth year over year. However, in 2024, reported net earnings sharply declined to 14,405 million, a significant reduction compared to the previous year.
Adjusted net earnings follow a similar upward trajectory from 16,150 million in 2020 to 23,188 million in 2023, indicating a generally positive underlying business performance once certain adjustments are considered. The sharp decline is also observed in 2024 with adjusted net earnings dropping to 14,150 million.
- Return on Assets (ROA)
-
Reported ROA remained relatively stable during the first four years, increasing from 7.81% in 2020 to a high of 8.19% in 2022 and holding steady at 8.18% in 2023. The ROA then dropped significantly in 2024 to 4.83%, reflecting diminished profitability relative to asset base.
Adjusted ROA exhibits a more varied pattern, starting at 8.19% in 2020 and declining to a low of 6.89% in 2022, before rebounding to 8.47% in 2023. Similar to reported ROA, it falls sharply in 2024 to 4.74%, indicating reduced operational efficiency when adjusted for certain items.
Overall, the data suggests a period of strong financial performance and growth through 2023, with both earnings and asset returns strengthening. The significant decrease in 2024 in both reported and adjusted figures signals a potential downturn or impairment impacting profitability and asset utilization. The consistent alignment between reported and adjusted metrics over the years, including the drop in 2024, reinforces the reliability of these performance trends.